Finished
Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging
NCT07069465 · Urology Clinics of North Texas · Updated 16 July 2025
- What is being tested
- flotufolastat F 18; Relugolix 120 MG; Serum PSA and Testosterone
- For
- Prostate Cancer
- Kind of study
- Tests a treatment or device on volunteers. Early phase 1.
- Who can join
- Ages Not stated. About 10 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 15 June 2024, ends 6 Nov 2024. Registered 16 July 2025.
- Results
- None posted yet.
In the researchers' words
This is a pilot, non-randomized, two-cohort interventional study in patients who meet the inclusion criteria, using an FDA- approved androgen deprivation agent for a 3 or 6-week course of treatment prior to standard-of-care RALP with PLND. The intent of the study is to determine the effect of ADT on PSMA expression as measured by PSMA-PET scan. A second PSMA-PET scan will be performed after ADT for either 3 or 6 weeks, depending on cohort, prior to RALP and PLND.
Sites
- Urology Clinics of North TexasDallas, Texas, United States